| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |